Local Control and Toxicity of a Simultaneous Integrated Boost for Dose Escalation in Locally Advanced Esophageal Cancer: Interim Results from a Prospective.

Slides:

Advertisements

Similar presentations

Differential Response to Preoperative Chemoradiation and Surgery in Esophageal Adenocarcinomas Based on Presence of Barrett's Esophagus and Symptomatic.

Advertisements

A Prognostic Scoring Model for the Utility of Induction Chemotherapy Prior to Neoadjuvant Chemoradiotherapy in Esophageal Cancer Mian Xi, MD, Zhongxing.

The evolution of treatment outcomes for resected stage IIIA non–small cell lung cancer over 16 years at a single institution Linda W. Martin, MD, Arlene.

Preoperative Chemo-Radiation-Induced Ulceration in Patients with Esophageal Cancer: A Confounding Factor in Tumor Response Assessment in Integrated Computed.

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies Sai-Hong Ignatius Ou, MD,

Prospective Study of Patient-Reported Symptom Burden in Patients With Non–Small- Cell Lung Cancer Undergoing Proton or Photon Chemoradiation Therapy Xin.

Jennifer C. Ho, MD, Quynh-Nhu Nguyen, MD, Heng Li, PhD, Pamela K

Disparities in Treatment of Patients with Inoperable Stage I Non–Small Cell Lung Cancer: A Population-Based Analysis Matthew Koshy, MD, Renuka Malik,

SC17.02 Lung Cancer in China: Challenges and Perspectives

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database Alex.

Intensity-Modulated Radiotherapy After Extrapleural Pneumonectomy in the Combined- Modality Treatment of Malignant Pleural Mesothelioma Alexander Chi,

Michael C. Roach, MD, Gregory M. M. Videtic, MD, CM, FRCPC, Jeffrey D

Utility of PET, CT, and EUS to Identify Pathologic Responders in Esophageal Cancer Stephen G. Swisher, MD, Mary Maish, MD, Jeremy J. Erasmus, MD, Arlene.

Neoadjuvant chemoradiotherapy followed by surgery for esophageal adenocarcinoma: Significance of microscopically positive circumferential radial margins

Andreas Rimner, MD, Daniel R. Gomez, MD, Abraham J

Final Results of NRG Oncology RTOG 0246: An Organ-Preserving Selective Resection Strategy in Esophageal Cancer Patients Treated with Definitive Chemoradiation

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database Alex.

Results of Surgical Treatment for Patients with Small Cell Lung Cancer

Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901 Stephen L. Graziano,

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

Long-Term Outcomes of Salvage Stereotactic Ablative Radiotherapy for Isolated Lung Recurrence of Non–Small Cell Lung Cancer: A Phase II Clinical Trial

Patterns of Care and Treatment Outcomes of Elderly Patients with Stage I Esophageal Cancer: Analysis of the National Cancer Data Base Amy C. Moreno,

Influence of Preoperative Radiation Field on Postoperative Leak Rates in Esophageal Cancer Patients after Trimodality Therapy Aditya Juloori, BS, Susan.

Histopathologic Response Criteria Predict Survival of Patients with Resected Lung Cancer After Neoadjuvant Chemotherapy Apar Pataer, MD, PhD, Neda Kalhor,

IA05.01 Lung Cancer Cases Journal of Thoracic Oncology

Brian N. Arnold, MD, Daniel C. Thomas, MD, MPH, Joshua E

Esophageal Cancer Located at the Neck and Upper Thorax Treated with Concurrent Chemoradiation: A Single-Institution Experience Shulian Wang, MD, Zhongxing.

Thymoma—A Clinico-Pathological Long-Term Study with Emphasis on Histology and Adjuvant Radiotherapy Dose Thomas Harnath, MD, Alexander Marx, MD, Philipp.

Improved Overall Survival with Aggressive Primary Tumor Radiotherapy for Patients with Metastatic Esophageal Cancer David M. Guttmann, MD, MTR, Nandita.

The Role of Consolidation Therapy for Stage III Non-Small Cell Lung Cancer With Persistent N2 Disease After Induction Chemotherapy Arya Amini, BA, Arlene.

Lung Cancer and Prognosis in Taiwan: A Population-Based Cancer Registry Bing-Yen Wang, MD, Jing-Yang Huang, Ching-Yuan Cheng, MD, Ching-Hsiung Lin, MD,

Technical Advances of Radiation Therapy for Thymic Malignancies

Intratumoral Lymphatic Vessel Involvement is an Invasive Indicator of Completely Resected Pathologic Stage I Non-small Cell Lung Cancer Masahiko Harada,

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Association between Congenital Lung Malformations and Lung Tumors in Children and Adults: A Systematic Review Arianna Casagrande, MD, Federica Pederiva,

Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature Caicun Zhou, MD, PhD, Luan Di Yao, MD

Re-evaluation of the Role of Postoperative Radiotherapy and the Impact of Radiation Dose for Non–Small-Cell Lung Cancer Using the National Cancer Database

Daniel Morgensztern, MD, Boone Goodgame, MD, Maria Q

Brendon M. Stiles, MD, Mohamed K. Kamel, MD, Sebron W

Re-evaluating the Optimal Radiation Dose for Definitive Chemoradiotherapy for Esophageal Squamous Cell Carcinoma Liru He, MD, Pamela K. Allen, PhD, Adam.

PD5-2-5: Local therapy of primary diseae improves survival in non-small cell lung cancer metastatic to a single organ - a lesson from brain metastases

Survival Differences by Gender for Resected Non-small Cell Lung Cancer: A Retrospective Analysis of 12,509 Cases in a Japanese Lung Cancer Registry Study

Thoracoscopic Lobectomy Produces Long-Term Survival Similar to That with Open Lobectomy in Cases of Non–Small Cell Lung Carcinoma: A Propensity-Matched.

Nivolumab-Induced Acute Diabetes Mellitus and Hypophysitis in a Patient with Advanced Pulmonary Pleomorphic Carcinoma with a Prolonged Tumor Response

Appropriateness of Surgical Approach in Black Patients with Lung Cancer—15 Years Later, Little Has Changed Emanuela Taioli, MD, PhD, Raja Flores, MD

Rachel Benamore, MB BChir, MRCP, FRCR, Frances A

Vamsidhar Velcheti, MD Journal of Thoracic Oncology

Patterns of Failure, Toxicity, and Survival after Extrapleural Pneumonectomy and Hemithoracic Intensity-Modulated Radiation Therapy for Malignant Pleural.

Dose-per-Fraction Escalation of Accelerated Hypofractionated Three-Dimensional Conformal Radiotherapy in Locally Advanced Non-small Cell Lung Cancer

Relationship between Response and Survival in More Than 50,000 Patients with Advanced Non-small Cell Lung Cancer Treated with Systemic Chemotherapy in.

Nabil P. Rizk, MD, Venkatraman E. Seshan, PhD, Manjit S

Gemcitabine in Brief versus Prolonged Low-Dose Infusion, both Combined with Cisplatin, for Advanced Non-small Cell Lung Cancer: A Randomized Phase II.

Should Large Cell Neuroendocrine Lung Carcinoma be Classified and Treated as a Small Cell Lung Cancer or with Other Large Cell Carcinomas? John M. Varlotto,

Compound Uncommon EGFR Mutations in a Patient with Advanced NSCLC and Durable Response to Sequential EGFR Targeted Therapies Mary Linton B Peters, MD,

Immune-Modulating Vaccines in Non-small Cell Lung Cancer

A Phase I Study of Gefitinib with Concurrent Dose-Escalated Weekly Docetaxel and Conformal Three-Dimensional Thoracic Radiation Followed by Consolidative.

A Prognostic Scoring Model for the Utility of Induction Chemotherapy Prior to Neoadjuvant Chemoradiotherapy in Esophageal Cancer Mian Xi, MD, Zhongxing.

Association between Systemic Chemotherapy before Chemoradiation and Increased Risk of Treatment-Related Pneumonitis in Esophageal Cancer Patients Treated.

Genetic Changes in Squamous Cell Lung Cancer: A Review

Carcinoma of the esophagus: Prognostic significance of histologic type

Stage I Non-small Cell Lung Cancer: Results for Surgery in a Patterns-of-Care Study in Sydney and for High-Dose Concurrent End-Phase Boost Accelerated.

Influence of Ground Glass Opacity and the Corresponding Pathological Findings on Survival in Patients with Clinical Stage I Non–Small Cell Lung Cancer

Large clinical databases for the study of lung cancer: Making up for the failure of randomized trials Chi-Fu Jeffrey Yang, MD, Matthew G. Hartwig, MD,

Induction Therapy For Locally Advanced Thymoma

A Randomized, Phase II Trial of Two Dose Levels of Temsirolimus (CCI-779) in Patients with Extensive-Stage Small-Cell Lung Cancer Who Have Responding.

Time Trends of Surgical Outcome in Patients with Non-small Cell Lung Cancer Takeshi Hanagiri, MD, PhD, Tetsuro Baba, MD, PhD, Tetsuya So, MD, PhD, Manabu.

Long-Term Follow-Up of a Phase I/II Trial of Dose Escalating Three-Dimensional Conformal Thoracic Radiation Therapy with Induction and Concurrent Carboplatin.

Improved Long-Term Outcome With Chemoradiotherapy Strategies in Esophageal Cancer Stephen G. Swisher, MD, Wayne Hofstetter, MD, Ritsuko Komaki, MD, Arlene.

Jenifer L. Marks, MD, Wayne Hofstetter, MD, Arlene M

Prognostic Significance of Tumor Size in Patients with Stage III Non–Small-Cell Lung Cancer: A Surveillance, Epidemiology, and End Results (SEER) Survey.

Presentation transcript:

Local Control and Toxicity of a Simultaneous Integrated Boost for Dose Escalation in Locally Advanced Esophageal Cancer: Interim Results from a Prospective Phase I/II Trial James W. Welsh, MD, Steven N. Seyedin, MD, Pamela K. Allen, PhD, Wayne L. Hofstetter, MD, Jaffer A. Ajani, MD, Joe Y. Chang, MD, PhD, Daniel R. Gomez, MD, Arya Amini, MD, Stephen G. Swisher, MD, Mariela A. Blum, MD, Ahmed I. Younes, MD, Quynh-Nhu Nguyen, MD, Bruce D. Minsky, MD, Jeremy J. Erasmus, MD, Jeffrey H. Lee, MD, Manoop Bhutani, MD, Ritsuko U. Komaki, MD Journal of Thoracic Oncology Volume 12, Issue 2, Pages 375-382 (February 2017) DOI: 10.1016/j.jtho.2016.10.013 Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 First sites of failure among patients with esophageal cancer who received a simultaneous integrated boost (dose escalation) to 63 Gy to the gross tumor volume by intensity-modulated radiation therapy and a comparison group who received intensity-modulated radiation therapy to 50.4 Gy without a boost dose. NED, no evidence of disease. Journal of Thoracic Oncology 2017 12, 375-382DOI: (10.1016/j.jtho.2016.10.013) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Figure 2 Local failure–free survival proportions according to whether patients received a boost dose to the gross tumor volume (dose escalation) or a conventional dose of 50.4 Gy for locally advanced esophageal cancer, both delivered as intensity-modulated radiation therapy. Rates were no different by treatment group (p = 0.30) (A) or when patients were stratified by tumor histologic type (p = 0.29 for adenocarcinoma [B] or p = 0.90 for squamous cell carcinoma [C]). Patients with adenocarcinoma with a pathologic complete response to chemoradiation seemed to have better local control after simultaneous integrated boost–intensity-modulated radiation therapy than after convention-dose therapy, but this apparent difference was not statistically significant (p = 0.22) (D). Journal of Thoracic Oncology 2017 12, 375-382DOI: (10.1016/j.jtho.2016.10.013) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions